Provigil (Modafinil) Patent Expiration, LOE Window & CMS Spending
Provigil (Modafinil) by Nuvo (Ireland) Dac: Off-Patent Genericized (AB Competition), 7 AB generics, $33.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Nuvo (Ireland) Dac |
| FDA Application & Pathway | N020717 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $33.1M |
| 2024 Medicare Part D Spend | $13.2M |
| 2024 Medicaid Spend | $19.8M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 18.0% 2-yr change) |